Research Progress on the Role of Immune Cell Dysfunction in the Occurrence and Development of Liver Failure

Tangwei MOU; Dan LIANG; Yu ZHAO; Yiqun KUANG

doi:10.12259/j.issn.2095-610X.S20250901

Volume 46 Issue 9

Sep. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(9): 1-14

Tangwei MOU, Dan LIANG, Yu ZHAO, Yiqun KUANG. Research Progress on the Role of Immune Cell Dysfunction in the Occurrence and Development of Liver Failure[J]. Journal of Kunming Medical University, 2025, 46(9): 1-14. doi: 10.12259/j.issn.2095-610X.S20250901

Citation:

Tangwei MOU, Dan LIANG, Yu ZHAO, Yiqun KUANG. Research Progress on the Role of Immune Cell Dysfunction in the Occurrence and Development of Liver Failure[J]. Journal of Kunming Medical University, 2025, 46(9): 1-14. doi: 10.12259/j.issn.2095-610X.S20250901

Citation:

PDF( 2914 KB)

Research Progress on the Role of Immune Cell Dysfunction in the Occurrence and Development of Liver Failure

doi: 10.12259/j.issn.2095-610X.S20250901

Research Center for Clinical Medicine，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

More Information

Corresponding author: 况轶群，博士，教授，博士生导师，云南省高层次引进人才（青年千人），昆明医科大学高层次引进人才（第四层次），昆明医科大学第一附属医院临床医学研究中心副主任（主持工作），主要从事HIV等病原体相关感染和免疫学研究。在国内外学术期刊发表论文83篇，其中SCI文章72篇，引用1282次；参编专著5部；申报专利10项（授权4项）；主持国家科技部、NSFC和省市级科研项目16项，参与14项。任世界病毒学会会员、华人抗体协会终身会员、中国性病艾滋病防治协会艾滋病病毒学专业委员会委员等；担任Signal Transduct Target Ther、Nat Comm、Gut Microbes、AIDS等30多个杂志审稿人；国家科技重大专项会议评审专家、NSFC等项目通信评审专家。曾获中国科学院“朱李月华优秀博士生奖”、中国免疫学会首届“青年学者奖”、Dalhousie大学“Reynolds博士后奖”、云南省卫生科技成果一等奖（2020）、云南省科学技术进步奖一等奖（2021）、云南省卫生科技成果二等奖（2023）、云南省科学技术进步奖二等奖（2024）等奖励和荣誉。
Received Date: 2025-05-21
Available Online: 2025-09-22
Publish Date: 2025-09-25

Abstract

Abstract

The liver, as the core metabolic organ of the human body, undertakes multiple critical physiological functions such as protein synthesis, xenobiotic metabolism, and immune regulation. Liver failure represents a major disease process in patients with end-stage liver disease, characterized clinically by coagulopathy, abnormal bilirubin metabolism, and multiple organ dysfunction. Depending on the disease course, liver failure can be classified into four types: acute, subacute, acute-on-chronic, and chronic. The pathogenic mechanisms are complex, involving interactions among various factors such as pathogen infections, dysregulation of the immune microenvironment, and gut microbiota disturbances, which pose significant challenges for clinical diagnosis and treatment. This review summarizes the abnormalities in innate and adaptive immune responses, as well as the molecular mechanisms of immune metabolic dysregulation during the occurrence and progression of liver failure. It further explores the pivotal role of immune cell dysfunction in the disease process, aiming to provide a theoretical basis for targeted immune therapies in liver failure.
- Liver failure,
- Immune cell function,
- Immune response,
- Immunometabolism,
- Targeted therapy

FullText(HTML)

References(76)

References

[1]	中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40(12): 2371-2387.
[2]	Mak L Y, Liu K, Chirapongsathorn S, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: Burden, trends, challenges and future directions[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(12): 834-851. doi: 10.1038/s41575-024-00967-4
[3]	Devarbhavi H, Asrani S K, Arab J P, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79(2): 516-537. doi: 10.1016/j.jhep.2023.03.017
[4]	Hernaez R, Kramer J R, Liu Y, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA[J]. J Hepatol, 2019, 70(4): 639-647. doi: 10.1016/j.jhep.2018.12.018
[5]	Khanam A, Kottilil S. Abnormal innate immunity in acute-on-chronic liver failure: Immunotargets for therapeutics[J]. Front Immunol, 2020, 11: 2013. doi: 10.3389/fimmu.2020.02013
[6]	Ahmed O, Robinson M W, O'Farrelly C. Inflammatory processes in the liver: Divergent roles in homeostasis and pathology[J]. Cell Mol Immunol, 2021, 18(6): 1375-1386. doi: 10.1038/s41423-021-00639-2
[7]	Wen Y, Lambrecht J, Ju C, et al. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities[J]. Cell Mol Immunol, 2021, 18(1): 45-56. doi: 10.1038/s41423-020-00558-8
[8]	Siwicki M, Gort-Freitas N A, Messemaker M, et al. Resident kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy[J]. Sci Immunol, 2021, 6(61): eabi7083. doi: 10.1126/sciimmunol.abi7083
[9]	Wu W, Sun S, Wang Y, et al. Circulating neutrophil dysfunction in HBV-related acute-on-chronic liver failure[J]. Front Immunol, 2021, 12: 620365. doi: 10.3389/fimmu.2021.620365
[10]	Liu K, Wang F S, Xu R. Neutrophils in liver diseases: Pathogenesis and therapeutic targets[J]. Cell Mol Immunol, 2021, 18(1): 38-44. doi: 10.1038/s41423-020-00560-0
[11]	Chauhan A, Sheriff L, Hussain M T, et al. The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure[J]. Nat Commun, 2020, 11(1): 1939. doi: 10.1038/s41467-020-15584-3
[12]	Kolodziejczyk A A, Federici S, Zmora N, et al. Acute liver failure is regulated by MYC-and microbiome-dependent programs[J]. Nat Med, 2020, 26(12): 1899-1911. doi: 10.1038/s41591-020-1102-2
[13]	Meijenfeldt F A, Stravitz R T, Zhang J, et al. Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome[J]. Hepatology, 2022, 75(3): 623-633. doi: 10.1002/hep.32174
[14]	Triantafyllou E, Pop O T, Possamai LA, et al. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure[J]. Gut, 2018, 67(2): 333-347. doi: 10.1136/gutjnl-2016-313615
[15]	Albillos A, Hera Ad Ade L, Reyes E, et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: Amelioration with norfloxacin[J]. J Hepatol, 2004, 40(4): 624-631. doi: 10.1016/j.jhep.2003.12.010
[16]	Wasmuth H E, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis[J]. J Hepatol, 2005, 42(2): 195-201. doi: 10.1016/j.jhep.2004.10.019
[17]	Triantafyllou E, Woollard K J, McPhail M J W, et al. The role of monocytes and macrophages in acute and acute-on-chronic liver failure[J]. Front Immunol, 2018, 9: 2948. doi: 10.3389/fimmu.2018.02948
[18]	Bernsmeier C, Pop O T, Singanayagam A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J]. Gastroenterology, 2015, 148(3): 603-615. e614. doi: 10.1053/j.gastro.2014.11.045
[19]	Leonhardt J, Haider R S, Sponholz C, et al. Circulating bile acids in liver failure activate TGR5 and induce monocyte dysfunction[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(1): 25-40. doi: 10.1016/j.jcmgh.2021.01.011
[20]	Trovato F M, Zia R, Napoli S, et al. Dysregulation of the lysophosphatidylcholine/autotaxin/lysophosphatidic acid axis in acute-on-chronic liver failure is associated with mortality and systemic inflammation by lysophosphatidic acid-dependent monocyte activation[J]. Hepatology, 2021, 74(2): 907-925. doi: 10.1002/hep.31738
[21]	Korf H, du Plessis J, van Pelt J, et al. Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity[J]. Gut, 2019, 68(10): 1872-1883. doi: 10.1136/gutjnl-2018-316888
[22]	Singanayagam A, Triantafyllou E. Macrophages in chronic liver failure: Diversity, plasticity and therapeutic targeting[J]. Front Immunol, 2021, 12: 661182. doi: 10.3389/fimmu.2021.661182
[23]	Nielsen M C, Hvidbjerg Gantzel R, Clària J, et al. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure[J]. Cells, 2020, 9(5): 1175. doi: 10.3390/cells9051175
[24]	Perugorria M J, Esparza-Baquer A, Oakley F, et al. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage[J]. Gut, 2019, 68(3): 533-546. doi: 10.1136/gutjnl-2017-314107
[25]	Triantafyllou E, Gudd C L, Mawhin M A, et al. PD-1 blockade improves kupffer cell bacterial clearance in acute liver injury[J]. J Clin Invest, 2021, 131(4): e140196. doi: 10.1172/JCI140196
[26]	Bai L, Kong M, Duan Z, et al. M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis[J]. Cell Death Dis, 2021, 12(1): 93. doi: 10.1038/s41419-020-03378-w
[27]	Zhang S, Jiang L, Hu H, et al. Pretreatment of exosomes derived from hUCMSCs with TNF-α ameliorates acute liver failure by inhibiting the activation of NLRP3 in macrophage[J]. Life Sci, 2020, 246: 117401. doi: 10.1016/j.lfs.2020.117401
[28]	Yu X, Zhou L, Deng Q, et al. rhIL-1Ra reduces hepatocellular apoptosis in mice with acute liver failure mainly by inhibiting the activities of kupffer cells[J]. Eur J Pharmacol, 2019, 854: 338-346. doi: 10.1016/j.ejphar.2019.03.031
[29]	Wang J, Liu Y, Ding H, et al. Mesenchymal stem cell-secreted prostaglandin E(2) ameliorates acute liver failure via attenuation of cell death and regulation of macrophage polarization[J]. Stem Cell Res Ther, 2021, 12(1): 15. doi: 10.1186/s13287-020-02070-2
[30]	Yu H, Yang W, Huang J, et al. GPR120 induces regulatory dendritic cells by inhibiting HK2-dependent glycolysis to alleviate fulminant hepatic failure[J]. Cell Death Dis, 2021, 13(1): 1. doi: 10.1038/s41419-021-04394-0
[31]	Wang Y, Wang Q, Wang B, et al. Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells[J]. Cell Death Dis, 2020, 11(11): 1024. doi: 10.1038/s41419-020-03219-w
[32]	Li SS, Yang M, Chen YP, et al. Dendritic cells with increased expression of suppressor of cytokine signaling 1(SOCS1) gene ameliorate lipopolysaccharide/d-galactosamine-induced acute liver failure[J]. Mol Immunol, 2018, 101: 10-18. doi: 10.1016/j.molimm.2018.05.016
[33]	Chen Y, Hou C, Yang N, et al. Regulatory Effect of JAK2/STAT3 on the immune function of endotoxin-tolerant dendritic cells and its involvement in acute liver failure[J]. J Clin Transl Hepatol, 2022, 10(5): 879-890. doi: 10.14218/JCTH.2021.00175
[34]	Li H, Zhai N, Wang Z, et al. Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection[J]. Gut, 2018, 67(11): 2035-2044. doi: 10.1136/gutjnl-2017-314098
[35]	Chen T, Zhu L, Zhou Y, et al. KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure[J]. Clin Immunol, 2013, 146(3): 207-216. doi: 10.1016/j.clim.2012.12.013
[36]	Zhang X, Zhu L, Zhou Y, et al. Interference with KCTD9 inhibits NK cell activation and ameliorates fulminant liver failure in mice[J]. BMC Immunol, 2018, 19(1): 20. doi: 10.1186/s12865-018-0256-x
[37]	Taru V, Szabo G, Mehal W, et al. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation[J]. J Hepatol, 2024, 81(5): 895-910. doi: 10.1016/j.jhep.2024.06.016
[38]	Huang S, Wang Y, Xie S, et al. Hepatic TGFβr1 deficiency attenuates lipopolysaccharide/D-galactosamine-induced acute liver failure through inhibiting GSK3β-Nrf2-Mediated hepatocyte apoptosis and ferroptosis[J]. Cell Mol Gastroenterol Hepatol, 2022, 13(6): 1649-1672. doi: 10.1016/j.jcmgh.2022.02.009
[39]	Xiang X, Feng D, Hwang S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice[J]. J Hepatol, 2020, 72(4): 736-745. doi: 10.1016/j.jhep.2019.11.013
[40]	Zhou T, Sun Y, Li M, et al. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway[J]. Cell Death Dis, 2018, 9(6): 590. doi: 10.1038/s41419-018-0670-2
[41]	Fu B, Yin S, Lin X, et al. PTPN14 aggravates inflammation through promoting proteasomal degradation of SOCS7 in acute liver failure[J]. Cell Death Dis, 2020, 11(9): 803. doi: 10.1038/s41419-020-03014-7
[42]	Du X X, Shi Y, Yang Y, et al. DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acute-on-chronic liver failure[J]. Liver Int, 2018, 38(2): 229-238. doi: 10.1111/liv.13503
[43]	Khanam A, Trehanpati N, Sarin S K. Increased interleukin-23 receptor (IL-23R) expression is associated with disease severity in acute-on-chronic liver failure[J]. Liver Int, 2019, 39(6): 1062-1070. doi: 10.1111/liv.14015
[44]	Zaccherini G, Weiss E, Moreau R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2021, 3(1): 100176. doi: 10.1016/j.jhepr.2020.100176
[45]	Moreau R. The pathogenesis of ACLF: The inflammatory response and immune function[J]. Semin Liver Dis, 2016, 36(2): 133-140. doi: 10.1055/s-0036-1583199
[46]	Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF[J]. J Hepatol, 2020, 72(4): 688-701. doi: 10.1016/j.jhep.2019.11.009
[47]	Filliol A, Piquet-Pellorce C, Raguénès-Nicol C, et al. RIPK1 protects hepatocytes from kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis[J]. J Hepatol, 2017, 66(6): 1205-1213. doi: 10.1016/j.jhep.2017.01.005
[48]	Yan Y Y, Lin S, Zhu Y Y. Damage-associated molecular patterns and liver failure[J]. Zhonghua Gan Zang Bing Za Zhi, 2016, 24(8): 636-640. doi: 10.3760/cma.j.issn.1007-3418.2016.08.017
[49]	Wu J, Han M, Li J, et al. Pattern recognition receptors and liver failure[J]. Crit Rev Immunol, 2019, 39(4): 289-311. doi: 10.1615/CritRevImmunol.2019031012
[50]	Qiang R, Liu X Z, Xu J C. The immune pathogenesis of acute-on-chronic liver failure and the danger hypothesis[J]. Front Immunol, 2022, 13: 935160. doi: 10.3389/fimmu.2022.935160
[51]	Ma M, Jiang W, Zhou R. DAMPs and DAMP-sensing receptors in inflammation and diseases[J]. Immunity, 2024, 57(4): 752-771. doi: 10.1016/j.immuni.2024.03.002
[52]	Fan X G, Pei S Y, Zhou D, et al. Melittin ameliorates inflammation in mouse acute liver failure via inhibition of PKM2-mediated Warburg effect[J]. Acta Pharmacol Sin, 2021, 42(8): 1256-1266. doi: 10.1038/s41401-020-00516-0
[53]	Rueschenbaum S, Ciesek S, Queck A, et al. Dysregulated adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure[J]. Front Immunol, 2020, 11: 534731. doi: 10.3389/fimmu.2020.534731
[54]	Khamri W, Abeles R D, Hou T Z, et al. Increased expression of cytotoxic T-lymphocyte-associated protein 4 by T cells, Induced by B7 in sera, reduces adaptive immunity in patients with acute liver failure[J]. Gastroenterology, 2017, 153(1): 263-276. e268. doi: 10.1053/j.gastro.2017.03.023
[55]	Wang F, Sun W, Xiao Q, et al. Peripheral T lymphocytes predict the severity and prognosis in patients with HBV-related acute-on-chronic liver failure[J]. Medicine, 2021, 100(5): e24075. doi: 10.1097/MD.0000000000024075
[56]	Du B, Teng J, Yin R, et al. Increased circulating T follicular helper cells induced via IL-12/21 in patients with acute on chronic hepatitis B liver failure[J]. Front Immunol, 2021, 12: 641362. doi: 10.3389/fimmu.2021.641362
[57]	Yu X, Yang F, Shen Z, et al. BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4⁺ T-cell exhaustion[J]. Nat Commun, 2024, 15(1): 1835. doi: 10.1038/s41467-024-46047-8
[58]	Yao J, Ji Y, Liu T, et al. Single-cell RNA sequencing shows T-cell exhaustion landscape in the peripheral blood of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. Gut Liver, 2024, 18(3): 520-530. doi: 10.5009/gnl220449
[59]	Zhou X, Li Y, Ji Y, et al. PD-1 Involvement in peripheral blood CD8⁺ T lymphocyte dysfunction in patients with acute-on-chronic liver failure[J]. J Clin Transl Hepatol, 2021, 9(3): 283-290. doi: 10.14218/JCTH.2020.00142
[60]	Tang L, Wang X, Zhao R, et al. Yi-Qi-Jian-Pi formula ameliorates immune function in acute-on-chronic liver failure by upregulating autophagy and mitochondrial biogenesis in CD8⁺ T lymphocytes[J]. J Ethnopharmacol, 2023, 308: 116276. doi: 10.1016/j.jep.2023.116276
[61]	Shen C, Yan W Z, Zhao CY, et al. Increased CD4⁺CD25⁺ regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients[J]. J Microbiol Immunol Infect, 2015, 48(2): 137-146. doi: 10.1016/j.jmii.2013.11.001
[62]	Tan N H, Chen B, Peng J, et al. Treg/Th17 cell balance in patients with hepatitis B virus-related acute-on-chronic liver failure at different disease stages[J]. Biomed Res Int, 2021, 2021: 9140602. doi: 10.1155/2021/9140602
[63]	Zhang Y, Zhang X, Han J, et al. Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure[J]. Hepatol Int, 2023, 17(4): 1000-1015. doi: 10.1007/s12072-023-10505-0
[64]	Wang X, Zhong Y, Zhang R, et al. Wenyang huazhuo tuihuang formula inhibits the Th17/Treg cell imbalance and protects against acute-on-chronic liver failure[J]. Evid Based Complement Alternat Med, 2022, 2022: 5652172. doi: 10.1155/2022/5652172
[65]	Chen L, Huang Y, Chen Y, et al. Resolvin D1 promotes the resolution of inflammation in the ACLF rat model by increasing the proportion of Treg cells[J]. Immun Inflamm Dis, 2023, 11(11): e1076. doi: 10.1002/iid3.1076
[66]	Farci P, Diaz G, Chen Z, et al. B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure[J]. Proc Natl Acad Sci U S A, 2010, 107(19): 8766-8771. doi: 10.1073/pnas.1003854107
[67]	Perez-Andres M, Paiva B, Nieto WG, et al. Human peripheral blood B-cell compartments: A crossroad in B-cell traffic[J]. Cytometry B Clin Cytom, 2010, 78(Suppl 1): S47-60. doi: 10.1002/cyto.b.20547
[68]	Martin V G, Wu Y B, Townsend C L, et al. Transitional B cells in early human B cell development-time to revisit the paradigm?[J]. Front Immunol, 2016, 7: 546. doi: 10.3389/fimmu.2016.00546
[69]	Cardoso C C, Matiollo C, Pereira C H J, et al. B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis[J]. Clin Res Hepatol Gastroenterol, 2021, 45(4): 101698. doi: 10.1016/j.clinre.2021.101698
[70]	Makowski L, Chaib M, Rathmell J C. Immunometabolism: From basic mechanisms to translation[J]. Immunol Rev, 2020, 295(1): 5-14. doi: 10.1111/imr.12858
[71]	Zhang I W, Curto A, López-Vicario C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure[J]. J Hepatol, 2022, 76(1): 93-106. doi: 10.1016/j.jhep.2021.08.009
[72]	Yu Z, Li J, Ren Z, et al. Switching from fatty acid oxidation to glycolysis improves the outcome of acute-on-chronic liver failure[J]. Adv Sci(Weinh), 2020, 7(7): 1902996. doi: 10.1002/advs.201902996
[73]	Clària J, Moreau R, Fenaille F, et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis[J]. Hepatology, 2019, 69(4): 1686-1701. doi: 10.1002/hep.30363
[74]	Park S H, Kwak J A, Jung S H, et al. Piperidylmethyloxychalcone improves immune-mediated acute liver failure via inhibiting TAK1 activity[J]. Exp Mol Med, 2017, 49(11): e392. doi: 10.1038/emm.2017.156
[75]	Bajaj J S, Reddy K R, O'Leary J G, et al. Serum levels of metabolites produced by intestinal microbes and lipid moieties independently associated with acute-on-chronic liver failure and death in patients with cirrhosis[J]. Gastroenterology, 2020, 159(5): 1715-1730. e1712. doi: 10.1053/j.gastro.2020.07.019
[76]	Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2022, 71(1): 163-175. doi: 10.1136/gutjnl-2020-323395

Relative Articles(20)

Relative Articles

[1]	Mengtian XIA, Beilei LI, Qian CHEN, Xiafei JIN, Feng WEI, Kaixuan WANG. The Effect of Microbial Metabolites on Immune Function Reconstruction of Aids Based on Mitochondrial Dysfunction. Journal of Kunming Medical University, 2025, 47(): 1-7.
[2]	Yifan LIU, Xing LUO, Tianci SONG, Zhihui YANG. Research Progress on Targeted Therapy and Resistance Mechanisms of Malignant Melanoma. Journal of Kunming Medical University, 2025, 46(2): 158-163. doi: 10.12259/j.issn.2095-610X.S20250222
[3]	Xingfen WANG, Yue DENG, Lihua YANG. Construction of Lipid Metabolism-Related Gene Prognostic Model and Immunoinfiltration Analysis of Ovarian Cancer. Journal of Kunming Medical University, 2024, 45(4): 17-25. doi: 10.12259/j.issn.2095-610X.S20240403
[4]	Xinrui WAN, Xiaoyan WANG, Lin WANG, Zhiqiang MA, Caixin LI, Shitao XU, Xingrui TANG, Hongyan Mao. Liver，Kidney and Immunologic Function and Drug Resistance in Patients with Nontuberculous Mycobacteria Infection. Journal of Kunming Medical University, 2023, 44(11): 113-119. doi: 10.12259/j.issn.2095-610X.S20231117
[5]	Yuhan SHI, Jing LI, Shuyuan LIU, Ting ZHAO, Jingsi YANG, Li SHI, Jiangli LIANG. Correlation of ERAP Gene Polymorphism with Antibody Response Induced by Sequential Immunization of Polio Vaccine. Journal of Kunming Medical University, 2023, 44(7): 22-28. doi: 10.12259/j.issn.2095-610X.S20230711
[6]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[7]	Chenxi LI, Zhuocen ZHA, Na LI, Lin LUO, Yang YANG, Wenlin CHEN. Selection of Intensive Adjuvant Therapy for Triple-positive Breast Cancer. Journal of Kunming Medical University, 2023, 44(10): 180-188. doi: 10.12259/j.issn.2095-610X.S20231020
[8]	Ting LI, Wei-Hua GUO. Research Progress of Glycolytic Reprogramming in Oral Squamous Cell Carcinoma. Journal of Kunming Medical University, 2023, 44(6): 155-161. doi: 10.12259/j.issn.2095-610X.S20230611
[9]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[10]	Qiao LUO, Hong SHI, Shaobo WANG. Role of α7-nicotinic Acetylcholine Receptor in Occurrence，Development and Therapy of Lung Cancer. Journal of Kunming Medical University, 2022, 43(2): 145-149. doi: 10.12259/j.issn.2095-610X.S20220226
[11]	Zhao XIANG, Jin-hui YANG. Clinical Efficacy of Non-biological Artificial Liver in 112 Patients with Liver Failure. Journal of Kunming Medical University, 2021, 42(12): 140-144. doi: 10.12259/j.issn.2095-610X.S20211034
[12]	Wei-sha ZHOU, Le ZHANG, Jing PENG, Shou-kun CHEN, Meng-jun LIU, Xiao FU, Zhi-fei TANG, Yun-xuan YUE. Effect of Plasma Exchange with Double Plasma Molecular Adsorption on Cytokines in Autoimmune Hepatitis with Liver Failure. Journal of Kunming Medical University, 2021, 42(4): 73-77. doi: 10.12259/j.issn.2095-610X.S20210414
[13]	Xiao-biao MA, Feng LUO, Yong-liang GAO, Jing-chao HAO. Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2020, 41(12): 60-67. doi: 10.12259/j.issn.2095-610X.S20201215
[14]	Zhang Le , Yue Yun Xuan , Xia Jia Wei , Peng Jing , Li Hui , Tang Li Bin . Evaluation on Efficacy of Non-biological Artificial Liver in Treatment of Liver Failure. Journal of Kunming Medical University, 2017, 38(01): 82-87.
[15]	Zhang Le , Tang Li Bin , Jiang Jian Jie , Xia Jia Wei , Lv Zheng Xuan , Li Yun Zhen , Han Liu Xin , Bai Bin . 非生物型人工肝技术治疗肝衰竭合并肝肾综合征. Journal of Kunming Medical University, 2017, 38(06): 36-39.
[16]	Wang Ya Ling . . Journal of Kunming Medical University,
[17]	Wang Jue . . Journal of Kunming Medical University,
[18]	Wang Hong Yue . . Journal of Kunming Medical University,
[19]	Chen Xian Yu . . Journal of Kunming Medical University,
[20]	Xu Ke Dong . . Journal of Kunming Medical University,